Thang Vo-Ta

Thang Vo-Ta is a Vietnamese-British entrepreneur and advocate for women's health innovation. He holds a BSc in Management from MIT and is completing an MSc in Translational Health Sciences at the University of Oxford. Thang has been recognised as a Sunday Times Maserati Top 100 entrepreneur and a Top 100 Manufacturing Leader by The Manufacturer, reflecting his track record of building products that bridge science and real-world patient need.

Thang co-founded Calla Lily Clinical Care alongside Dr Lara Zibners, drawing on both his operational expertise and Dr Zibners' lived experience as a clinician who underwent seven rounds of IVF. Together they developed Callavid® — a patented, tampon-shaped drug delivery device that provides leak-free, dosage-confident administration of vaginal therapeutics, beginning with progesterone for miscarriage prevention and IVF support. The device received FDA clearance and was named one of TIME magazine's Best Inventions of the Year.

As CEO, Thang leads Calla Lily Clinical Care's strategy, commercialisation, and team. The company is a certified B Corp and has secured over £1 million in Innovate UK grants, £1 million in NIHR funding for clinical trials, and raised £2.3 million to advance its platform — which also holds potential for oncology, menopause, and infectious disease indications. In early 2026, the company announced a strategic collaboration with Merck to further develop Callavid.